If you need more lookups,
subscriptions start at $34 USD/month.
Charity Scripture Location
San Francisco, CA, US
Charity Scripture Work
Chief Development Officer @ (March 2024 - Present)
Principal and Owner @ Sugar Tree Clinical Consulting, LLC (June 2023 - March 2024)
Chief Development Officer @ (December 2021 - June 2023)
VP Clinical Development and Medical Affairs @ (November 2019 - November 2021)
Sr Dir US and Global Medical Affairs @ (October 2018 - October 2019)
VP Business and Development Operations @ (November 2020 - November 2021)
Senior Director Oncology Clinical Development @ (March 2018 - October 2018)
Scientific Director Oncology Clinical Development @ AbbVie Stemcentrx an Abbvie Company (October 2016 - March 2018)
Associate Director Clinical Science @ (July 2015 - October 2016)
Associate Director Clinical Science @ (January 2015 - June 2015)
International Oncology Scientific Affairs, Heme and Onc TA Lead @ (October 2010 - December 2014)
Global Oncology Scientific Affairs, SrMgr @ (March 2008 - October 2010)
Early Development - Oncology Phase 1 Research @ (January 2006 - March 2008)
Clinical Pharmacology Research Core, Clinical Drug Development Fellow @ (April 2004 - January 2006)
Oncology Pharmacist @ (June 2002 - April 2004)
Intern @ Mylan Bertek Pharmaceuticals (January 1992 - January 1996)
Charity Scripture Education
Hamilton College
B.S. (Biochemistry/Molecular Biology)
The University of North Carolina at Chapel Hill
PharmD
Geisel School of Medicine at Dartmouth
M.S. (Pharmacology and Toxicology)
Charity Scripture Summary
Charity Scripture, based in San Francisco, CA, US, is currently a Chief Development Officer at Outpace Bio. Charity Scripture brings experience from previous roles at Sugar Tree Clinical Consulting, LLC and Bellicum Pharmaceuticals, Inc.. Charity Scripture holds a B.S. in Biochemistry/Molecular Biology @ Hamilton College. Charity Scripture has 2 emails and 3 mobile phone numbers on RocketReach.
Looking for a different Charity Scripture?
Find contact details for 700 million professionals.